Citadel Advisors
RARE icon

Citadel Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History

Citadel Advisors’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.68M Buy
128,100
+90,500
+241% +$2.04M ﹤0.01% 5486
2025
Q4 		$865K Sell
37,600
-132,200
-78% -$4.35M ﹤0.01% 7728
2025
Q3 		$5.11M Buy
169,800
+154,600
+1,017% +$4.64M ﹤0.01% 4326
2025
Q2 		$553K Sell
15,200
-2,600
-15% -$93.7K ﹤0.01% 8409
2025
Q1 		$645K Sell
17,800
-11,200
-39% -$466K ﹤0.01% 7914
2024
Q4 		$1.22M Sell
29,000
-5,800
-17% -$288K ﹤0.01% 6621
2024
Q3 		$1.93M Buy
34,800
+11,400
+49% +$581K ﹤0.01% 5608
2024
Q2 		$962K Sell
23,400
-7,400
-24% -$316K ﹤0.01% 6664
2024
Q1 		$1.44M Buy
30,800
+5,700
+23% +$269K ﹤0.01% 6174
2023
Q4 		$1.2M Sell
25,100
-1,200
-5% -$46.5K ﹤0.01% 6325
2023
Q3 		$938K Buy
26,300
+21,600
+460% +$856K ﹤0.01% 6689
2023
Q2 		$217K Buy
4,700
+1,100
+31% +$51K ﹤0.01% 9711
2023
Q1 		$144K Sell
3,600
-53,300
-94% -$2.29M ﹤0.01% 10701
2022
Q4 		$2.64M Sell
56,900
-36,400
-39% -$1.43M ﹤0.01% 4973
2022
Q3 		$3.86M Buy
93,300
+73,500
+371% +$3.78M ﹤0.01% 4309
2022
Q2 		$1.18M Buy
19,800
+11,800
+148% +$726K ﹤0.01% 6647
2022
Q1 		$581K Buy
8,000
+3,500
+78% +$244K ﹤0.01% 9036
2021
Q4 		$378K Sell
4,500
-4,400
-49% -$358K ﹤0.01% 10372
2021
Q3 		$803K Sell
8,900
-500
-5% -$45.2K ﹤0.01% 8692
2021
Q2 		$896K Sell
9,400
-6,300
-40% -$656K ﹤0.01% 8644
2021
Q1 		$1.79M Sell
15,700
-17,200
-52% -$2.34M ﹤0.01% 6672
2020
Q4 		$4.55M Buy
32,900
+22,800
+226% +$2.7M ﹤0.01% 3850
2020
Q3 		$830K Sell
10,100
-4,600
-31% -$381K ﹤0.01% 6374
2020
Q2 		$1.15M Buy
+14,700
New +$973K ﹤0.01% 5573
2019
Q4 		– Sell
-64,500
Closed -$2.76M – 9636
2019
Q3 		$2.76M Buy
64,500
+32,900
+104% +$1.79M ﹤0.01% 3986
2019
Q2 		$2.01M Buy
31,600
+26,900
+572% +$1.71M ﹤0.01% 4504
2019
Q1 		$326K Sell
4,700
-9,700
-67% -$554K ﹤0.01% 7491
2018
Q4 		$626K Sell
14,400
-24,100
-63% -$1.32M ﹤0.01% 6058
2018
Q3 		$2.94M Buy
38,500
+13,300
+53% +$1.08M ﹤0.01% 3765
2018
Q2 		$1.94M Buy
+25,200
New +$1.63M ﹤0.01% 4167
2018
Q1 		– Sell
-5,200
Closed -$241K – 8685
2017
Q4 		$241K Sell
5,200
-10,200
-66% -$500K ﹤0.01% 6807
2017
Q3 		$820K Buy
15,400
+2,700
+21% +$160K ﹤0.01% 4593
2017
Q2 		$789K Buy
12,700
+8,100
+176% +$488K ﹤0.01% 4444
2017
Q1 		$312K Sell
4,600
-3,200
-41% -$244K ﹤0.01% 5833
2016
Q4 		$548K Sell
7,800
-1,500
-16% -$106K ﹤0.01% 4758
2016
Q3 		$660K Sell
9,300
-1,200
-11% -$76.6K ﹤0.01% 4426
2016
Q2 		$514K Buy
10,500
+1,000
+11% +$64.7K ﹤0.01% 4442
2016
Q1 		$601K Buy
9,500
+5,500
+138% +$360K ﹤0.01% 4144
2015
Q4 		$449K Sell
4,000
-200
-5% -$20K ﹤0.01% 4605
2015
Q3 		$405K Buy
4,200
+1,700
+68% +$195K ﹤0.01% 5100
2015
Q2 		$256K Buy
+2,500
New +$194K ﹤0.01% 5977

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Citadel Advisors's RARE Position: Q1 2026 in Review

Citadel Advisors reduced its Ultragenyx Pharmaceutical (RARE) stake by 9.1% in Q1 2026, selling an estimated $4.74M and leaving 2,115,491 shares worth $44.3M. The position accounts for 0.01% of the portfolio, ranked #1472.

Citadel Advisors first reported a position in RARE in Q1 2014 and has held it in 48 quarters since. The position peaked at $177M in Q2 2021. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Citadel Advisors held 2,115,491 shares of Ultragenyx Pharmaceutical worth $44.3M as of Q1 2026.
  • Citadel Advisors sold 210,634 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $4.74M.
  • Ultragenyx Pharmaceutical made up 0.01% of Citadel Advisors's portfolio in Q1 2026, its #1472 holding.
  • Citadel Advisors first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and has held it in 48 quarters since.
  • Citadel Advisors's Ultragenyx Pharmaceutical position peaked at $177M in Q2 2021.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.